Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drug Dosing in Renal Diseases: Dose Adjustments Based on Drug Clearance and Elimination Rate Constant01:25

Drug Dosing in Renal Diseases: Dose Adjustments Based on Drug Clearance and Elimination Rate Constant

89
In patients with renal disease, dosage adjustments are necessary to maintain therapeutic plasma drug concentrations and prevent toxicity or subtherapeutic exposure. Renal impairment alters drug pharmacokinetics, especially in conditions like uremia, where changes such as prolonged elimination half-life and altered apparent volume of distribution can significantly affect drug disposition. These changes require careful modification of the dosing regimen to achieve the desired clinical...
89
Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance01:07

Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance

165
Drug transporters are critical in drug absorption, distribution, and excretion processes. They should be included in physiological-based pharmacokinetic (PBPK) models, which help predict human drug disposition. However, predicting this is challenging during drug development, especially when liver transport is involved. However, with a realistic representation of body transport processes, an accurate model may be possible.
A recent model describes pravastatin's hepatobiliary excretion,...
165
Dosage Regimen: Individualization01:24

Dosage Regimen: Individualization

80
Individualization in dosing regimens is the customization of medication doses for individual patients. Its necessity arises from the goal of maximizing therapeutic benefits while minimizing risks. This approach is pivotal because human responses to drugs can vary widely; what is effective for one person may be inadequate or excessive for another. Interpatient (intersubject) variability refers to differences in drug responses between individuals, while intrapatient (intrasubject) variability...
80
Dosage Regimens: Partial Pharmacokinetic Parameters01:01

Dosage Regimens: Partial Pharmacokinetic Parameters

64
It is not uncommon for complete drug pharmacokinetic profiles to remain elusive in pharmacokinetics. This necessitates certain educated assumptions by pharmacokineticists to determine appropriate dosage regimens without comprehensive pharmacokinetic data from animal or human studies. One prevalent assumption is setting the bioavailability factor, denoted as F, to 1 or 100%. This assumption caters to the scenario where a drug doesn't achieve full systemic absorption, resulting in the patient...
64
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

87
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
87
Pharmacokinetics: Drug–Drug Interactions01:25

Pharmacokinetics: Drug–Drug Interactions

136
Drug interactions occur when the pharmacological effect of one drug is altered by another substance, either enhancing or diminishing its activity. The drug whose activity is altered is known as the object drug, and the substance causing the alteration is called the agent drug or the precipitant. The net effects of these interactions are mostly undesirable, leading to decreased effectiveness or increased adverse effects. In rare cases, interactions can be beneficial, such as the enhanced...
136

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Pharmacometric Analysis of Cafedrine/Theodrenaline Versus Ephedrine on Maternal Hemodynamics and Neonatal Acidosis During Cesarean Section.

Pharmaceutics·2026
Same author

Integrating Kolmogorov-Arnold networks with ordinary differential equations for efficient, interpretable, and robust deep learning: Epidemiology of infectious diseases as a case study.

Infectious Disease Modelling·2026
Same author

Advancing rare disease therapeutics through digital twins: Opportunities in drug development and precision dosing.

Computational and structural biotechnology journal·2025
Same author

Modeling of lung-liver interaction during infection in a human fluidic organ-on-a-chip.

Scientific reports·2025
Same author

Azelastine Nasal Spray for Prevention of SARS-CoV-2 Infections: A Phase 2 Randomized Clinical Trial.

JAMA internal medicine·2025
Same author

Pharmacogenetic Implementation Studies-Lessons Learned From the PREPARE Study.

Clinical pharmacology and therapeutics·2025

Related Experiment Video

Updated: Nov 27, 2025

A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds
13:34

A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds

Published on: April 6, 2016

10.4K

Physiologically Based Precision Dosing Approach for Drug-Drug-Gene Interactions: A Simvastatin Network Analysis.

Jan-Georg Wojtyniak1,2, Dominik Selzer1, Matthias Schwab2,3,4

  • 1Clinical Pharmacy, Saarland University, Saarbrücken, Germany.

Clinical Pharmacology and Therapeutics
|December 6, 2020
PubMed
Summary

This study introduces a novel approach using physiologically based pharmacokinetic (PBPK) modeling to predict complex drug-drug-gene interactions (DDGIs) for simvastatin. The findings pave the way for precision dosing to reduce adverse drug reactions.

More Related Videos

Biosensor-based High Throughput Biopanning and Bioinformatics Analysis Strategy for the Global Validation of Drug-protein Interactions
08:31

Biosensor-based High Throughput Biopanning and Bioinformatics Analysis Strategy for the Global Validation of Drug-protein Interactions

Published on: December 1, 2020

5.3K
Network Pharmacology Prediction and Metabolomics Validation of the Mechanism of Fructus Phyllanthi against Hyperlipidemia
11:06

Network Pharmacology Prediction and Metabolomics Validation of the Mechanism of Fructus Phyllanthi against Hyperlipidemia

Published on: April 7, 2023

2.5K

Related Experiment Videos

Last Updated: Nov 27, 2025

A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds
13:34

A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds

Published on: April 6, 2016

10.4K
Biosensor-based High Throughput Biopanning and Bioinformatics Analysis Strategy for the Global Validation of Drug-protein Interactions
08:31

Biosensor-based High Throughput Biopanning and Bioinformatics Analysis Strategy for the Global Validation of Drug-protein Interactions

Published on: December 1, 2020

5.3K
Network Pharmacology Prediction and Metabolomics Validation of the Mechanism of Fructus Phyllanthi against Hyperlipidemia
11:06

Network Pharmacology Prediction and Metabolomics Validation of the Mechanism of Fructus Phyllanthi against Hyperlipidemia

Published on: April 7, 2023

2.5K

Area of Science:

  • Pharmacology and Toxicology
  • Computational Biology
  • Genetics

Background:

  • Adverse drug reactions (ADRs) are a significant cause of mortality, often mediated by drug-drug interactions (DDIs) and drug-gene interactions (DGIs).
  • Physiologically based pharmacokinetic (PBPK) modeling is an established tool for optimizing pharmacotherapy in the context of DDIs and DGIs.
  • Extending PBPK modeling to complex drug-drug-gene interaction (DDGI) networks is crucial for advancing precision dosing.

Purpose of the Study:

  • To develop and validate a novel PBPK modeling approach for predicting complex DDGI scenarios.
  • To establish a whole-body PBPK network for simvastatin incorporating genetic polymorphisms and perpetrator drugs.
  • To optimize simvastatin dosing recommendations within a DDGI network using simulations and a decision support system.

Main Methods:

  • Construction of a whole-body PBPK network for simvastatin.
  • Inclusion of three key genetic polymorphisms (SLCO1B1, ABCG2, CYP3A5) and four interacting drugs (clarithromycin, gemfibrozil, itraconazole, rifampicin).
  • Performing extensive network simulations and optimizing 10,368 DDGI scenarios using an exposure marker cost function.

Main Results:

  • A comprehensive DDGI network for simvastatin was simulated and optimized.
  • Dose recommendations derived from the PBPK model were integrated into a digital decision support system.
  • The model, while covering a fraction of potential DDGIs, demonstrates the feasibility of PBPK-guided precision dosing.

Conclusions:

  • PBPK modeling can be extended to predict complex DDGI scenarios, offering a pathway to personalized pharmacotherapy.
  • The developed digital decision support system provides a practical tool for optimizing simvastatin dosing.
  • This work represents a foundational step towards integrating comprehensive PBPK-based precision dosing into routine clinical practice to mitigate ADR risks.